摘要
血管生成在肿瘤的发生和发展中起了重要的作用。抗血管生成已成为肿瘤治疗的一个重要手段,贯穿肿瘤治疗的全过程。血管内皮生长因子受体酪氨酸激酶抑制剂(VEGFR-TKI)是小分子抗肿瘤血管生成的药物。本文介绍国内外已上市和正处于研发阶段的VEGFR-TKIs,其单药、与化疗药物联用、与靶向药物联用的治疗模式提高了晚期非小细胞肺癌(NSCLC)的客观缓解率(ORR),延长了无进展生存期(PFS),但在延长总生存期(OS)方面未见优势。并且,VEGFR-TKIs的不良反应较大。如何提高疗效,减少不良反应,将是今后研究的方向。
Angiogenesis plays an important role in tumor genesis and development. Therefore, anti-angiogenic therapy has be- come an important part in cancer therapy and throughout the entire therapy process. Vascular endothelial growth factor receptor tyrosine kinase inhibitor （VEGFR-TKI） is small molecular anti-angiogenic drug. This article introduces the domestic and international listed and researching VEGFR-TKIs. The models of single-agent/combined with chemotherapy drugs/combined with targeted drugs can im- prove the objective response rates （ORR）of advanced non-small cell lung cancer （NSCLC） , lengthen progression-free survival（PFS）. But it was failed to lengthen overall survival（OS）. And the adverse effects of VEGFR-TKIs were greater. How to improve the efficacy and reduce adve^e effects will be the direction of future research.
出处
《临床肿瘤学杂志》
CAS
2017年第9期845-850,共6页
Chinese Clinical Oncology
基金
福建省卫生计生委青年课题基金资助项目(2015-1-14)
关键词
非小细胞肺癌
血管内皮生长因子受体酪氨酸激酶抑制剂
客观缓解率
无进展生存期
总生存期
Non-small cell lung cancer （NSCLC）
Vascular endothelial growth factor receptor tyrosine kinase inhibitors（VEGFR-TKIs）
Objective response rates （ORR）
Progression-free survival（PFS）
Overall survival（OS）
